# EyePoint Expects COMO, CAPRI Phase 3 Data in Early Q4 2027

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/55860
Published: 2026-11-12T20:21:05.000Z
Updated: 2026-11-12T20:21:05.000Z
Section: Business

> The company is focusing its Phase 3 program on DURAVYU for diabetic macular edema.

EyePoint expects top-line data from its COMO and CAPRI studies early in the fourth quarter of 2027. The studies are part of the company’s Phase 3 program in diabetic macular edema (DME), which focuses on DURAVYU.

The expected data window is early Q4 2027.